title: Outcomes from ovarian hyperstimulation following the sole administration of gonadotrophin-releasing hormone agonist in the context of in vitro fertilization: report of two cases and review of the literature.
abstract: OBJECTIVE
  To report the outcomes from two cases of ovarian stimulation following the sole administration of gonadotrophin-releasing hormone agonist (GnRHa) in the context of in vitro fertilization (IVF).
  
  
  METHODS
  A case study was conducted.
  
  
  METHODS
  National Referral Unit of Reproductive Medicine.
  
  
  METHODS
  Two infertile women undergoing IVF participated in the study.
  
  
  METHODS
  Controlled ovarian hyperstimulation using a long protocol. GnRHa (Buserelin) was started in the luteal phase, in a dose of 600 µg/day, for 12 days.
  
  
  METHODS
  Number of retrieved oocytes, fertilization rate, number of embryos transferred, implantation rate, ongoing pregnancy, and live birth.
  
  
  RESULTS
  Both women underwent egg retrieval and transfer of good quality embryos. One of them conceived and recently gave birth to a healthy full-term baby.
  
  
  CONCLUSIONS
  The ovarian hyperstimulation after the sole administration of GnRHa is a rare condition. Oocyte retrieval may be a reasonable treatment under these circumstances instead of cycle cancellation. As far as it is known, this is the third case reported of a live birth following the sole administration of GnRHa in the context of IVF.
authors.affiliation: Department of Obstetrics and Gynecology, Unit of Reproductive Medicine, Vila Nova de Gaia/Espinho Hospital Center, Vila Nova de Gaia, Portugal. evepinto@gmail.com
authors.forename: Evelin
authors.initials: E
authors.lastname: Pinto
authors.forename: Sueli
authors.initials: S
authors.lastname: Pinelo
authors.forename: Marta
authors.initials: M
authors.lastname: Osório
authors.forename: Carla
authors.initials: C
authors.lastname: Ferreira
authors.forename: Helena
authors.initials: H
authors.lastname: Serra
authors.forename: Ilda
authors.initials: I
authors.lastname: Pires
authors.forename: António
authors.initials: A
authors.lastname: Barbosa
authors.forename: Helena
authors.initials: H
authors.lastname: Figueiredo
authors.forename: Eduarda
authors.initials: E
authors.lastname: Felgueira
authors.forename: Angelina
authors.initials: A
authors.lastname: Tavares
mesh_terms: D000328:Adult; D002064:Buserelin / Q000008:administration & dosage / Q000009:adverse effects*; D004624:Embryo Transfer; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage / Q000009:adverse effects*; D005307:Fertilization in Vitro; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D007247:Infertility, Female / Q000628:therapy*; D016471:Ovarian Hyperstimulation Syndrome / Q000517:prevention & control; D010062:Ovulation Induction / Q000009:adverse effects*; D011247:Pregnancy; D047929:Term Birth; D017211:Treatment Failure
chemical_list: D005300:Fertility Agents, Female; D007987:Gonadotropin-Releasing Hormone; D002064:Buserelin